EVH Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of -3.72% compared to Evolent Health's net margin of 3.36%. Evolent Health's return on equity of -6.81% beat Astrana Health's return on equity of 12.67%.

Evolent Health has a consensus price target of --, signalling upside risk potential of 123.62%. On the other hand Astrana Health has an analysts' consensus of $64.5000 which suggests that it could grow by 91.4%. Given that Evolent Health has higher upside potential than Astrana Health, analysts believe Evolent Health is more attractive than Astrana Health.

Evolent Health has a beta of 1.448, which suggesting that the stock is 44.822% more volatile than S&P 500. In comparison Astrana Health has a beta of 1.134, suggesting its more volatile than the S&P 500 by 13.363%.

Evolent Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolent Health pays -16.63% of its earnings as a dividend. Astrana Health pays out 102.24% of its earnings as a dividend.

Evolent Health quarterly revenues are $621.4M, which are larger than Astrana Health quarterly revenues of $478.7M. Evolent Health's net income of -$23.1M is lower than Astrana Health's net income of $16.1M. Notably, Evolent Health's price-to-earnings ratio is -- while Astrana Health's PE ratio is 25.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health is 0.53x versus 0.93x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Biote has a net margin of -3.72% compared to Evolent Health's net margin of 20.83%. Evolent Health's return on equity of -6.81% beat Biote's return on equity of --.

Evolent Health has a consensus price target of --, signalling upside risk potential of 123.62%. On the other hand Biote has an analysts' consensus of -- which suggests that it could grow by 62.79%. Given that Evolent Health has higher upside potential than Biote, analysts believe Evolent Health is more attractive than Biote.

Evolent Health has a beta of 1.448, which suggesting that the stock is 44.822% more volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Evolent Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolent Health pays -16.63% of its earnings as a dividend. Biote pays out 262.18% of its earnings as a dividend.

Evolent Health quarterly revenues are $621.4M, which are larger than Biote quarterly revenues of $51.4M. Evolent Health's net income of -$23.1M is lower than Biote's net income of $10.7M. Notably, Evolent Health's price-to-earnings ratio is -- while Biote's PE ratio is 23.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health is 0.53x versus 1.06x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of -3.72% compared to Evolent Health's net margin of 8.15%. Evolent Health's return on equity of -6.81% beat Cryo-Cell International's return on equity of --.

Evolent Health has a consensus price target of --, signalling upside risk potential of 123.62%. On the other hand Cryo-Cell International has an analysts' consensus of $9.00 which suggests that it could grow by 14.94%. Given that Evolent Health has higher upside potential than Cryo-Cell International, analysts believe Evolent Health is more attractive than Cryo-Cell International.

Evolent Health has a beta of 1.448, which suggesting that the stock is 44.822% more volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.501, suggesting its less volatile than the S&P 500 by 49.887%.

Evolent Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 3.19% to investors and pays a quarterly dividend of $0.25 per share. Evolent Health pays -16.63% of its earnings as a dividend. Cryo-Cell International pays out -- of its earnings as a dividend.

Evolent Health quarterly revenues are $621.4M, which are larger than Cryo-Cell International quarterly revenues of $8M. Evolent Health's net income of -$23.1M is lower than Cryo-Cell International's net income of $655.8K. Notably, Evolent Health's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health is 0.53x versus 2.03x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of -3.72% compared to Evolent Health's net margin of -12.84%. Evolent Health's return on equity of -6.81% beat P3 Health Partners's return on equity of -26.35%.

Evolent Health has a consensus price target of --, signalling upside risk potential of 123.62%. On the other hand P3 Health Partners has an analysts' consensus of -- which suggests that it could grow by 228.95%. Given that P3 Health Partners has higher upside potential than Evolent Health, analysts believe P3 Health Partners is more attractive than Evolent Health.

Evolent Health has a beta of 1.448, which suggesting that the stock is 44.822% more volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Evolent Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolent Health pays -16.63% of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

Evolent Health quarterly revenues are $621.4M, which are larger than P3 Health Partners quarterly revenues of $362.1M. Evolent Health's net income of -$23.1M is higher than P3 Health Partners's net income of -$46.5M. Notably, Evolent Health's price-to-earnings ratio is -- while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health is 0.53x versus 0.02x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.